本文へスキップ

○○町、ビルダー子ども学習



ACCESS 

業績publications etc.

英文原著論文・英文総説 ORIGINAL & REVIEW ARTICLES (International)

  • 【New!!】 Haitani T, Kobayashi M, Koyasu S, Akamatsu S, Suwa T, Onodera Y, Nam JM, Nguyen PTL, Menju T, Date H, Ogawa O, *Harada H.
    Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase.
    Cancer Lett. 528:76-84. 2022.
  • 【New!!】 Miki K, Zhang ZD, Kaneko K, Kakiuchi Y, Kojima K, Enomoto A, Oe M, Nogita K, Murata Y, Harada H, Ohe K.
    Amphiphilic γ-cyclodextrin-fullerene complexes with photodynamic activity.
    Mater Adv. 3:312-317. 2022.
  • 【New!!】 Suwa T, Kobayashi M, Shirai Y, Nam JM, Tabuchi Y, Takeda N, Akamatsu S, Ogawa O, Mizowaki T, Hammond EM, *Harada H.
    SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization.
    JCI Insight. 6:e148135. 2021.
  • Sakai M, Takahashi N, Ikeda H, Furutani Y, Higuchi S, Suzuki T, Dohmae N, Kobayashi S, Harada H, Kojima S, Matsuura T, Hattori A, Kakeya H.
    Design, synthesis, and target identification of new hypoxia-inducible factor 1 (HIF-1) inhibitors with 1-alkyl-1H-pyrazole-3-carboxamide moiety.
    Bioorg Med Chem. 46:116375. 2021.
  • Miki K, Imaizumi N, Nogita K, Oe M, Mu H, Huo W, Harada H, Ohe K.
    MMP2-activatable photoacoustic tumor imaging probes based on Al-and Si-naphthalocyanines.
    Bioconjug Chem. 32:1773-1781. 2021.
  • Uba T, Matsuo Y, Sumi C, Shoji C, Nishi K, Kusunoki M, Harada H, Kimura H, Bono H, Hirota K.
    Polysulfide inhibits hypoxia-inducible factor activation in a mitochondria-dependent manner.
    Mitochondrion. 59:255-266. 2021.
  • Huo W, Miki K, Tokunaga D, Mu H, Oe M, Harada H, Ohe K.
    Dual-stimuli-responsive probes for detection of ovarian cancer cells and quantification of both pH and enzyme activity.
    Bull Chem Soc Jpn. 94:2068-2075. 2021.
  • Shirai Y, Chow CCT, Kambe G, Suwa T, Kobayashi M, Takahashi I, *Harada H, *Nam JM.
    An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor.
    Cancers. 13:2813. 2021.
  • Suwa T, Kobayashi M, Nam JM, *Harada H.
    Tumor microenvironment and radioresistance.
    Exp Mol Med (NPG). 53:1029-1035. 2021.
  • Maruoka M, Zhang P, Mori H, Imanishi E, Packwood DM, Harada H, Kosako H, Suzuki J.
    Caspase cleavage releases a nuclear protein fragment that stimulates phospholipidscrambling at the plasma membrane.
    Mol Cell. 81:1397-1410. 2021.
  • Mu H, Miki K, Harada H, Tanaka K, Nogita K, Ohe K.
    pH-activatable cyanine dyes for selective tumor imaging using near-infrared fluorescence and photoacoustic modalities.
    ACS Sens. 6:123-129. 2021.
  • Yamayoshi A, Oyama S, Kishimoto Y, Konishi R, Yamamoto T, Kobori A, Harada H, Ashihara E, Sugiyama H, Murakami A.
    Development of antibody-oligonucleotide complexes for targeting exosomal microRNA.
    Pharmaceutics. 12:545. 2020.
  • Furukawa S, Nagamatsu A, Nenoi M, Fujimori A, Kakinuma S, Katsube T, Wang B, Tsuruoka C, Shirai T, Nakamura AJ, Sakaue-Sawano A, Miyawaki A, Harada H, Kobayashi M, Kobayashi J, Kunieda T, Funayama T, Suzuki M, Miyamoto T, Hidema J, Yoshida Y, Takahashi A.
    Space Radiation Biology for "Living in Space".
    BioMed Res Int'l. 2020:4703286. 2020.
  • Roudkenar MH, Fukumoto M, Roushandeh AM, Kuwahara Y, Uroshihara Y, Harada H, Fukumoto M.
    Disturbance in the regulation of miR 17-92 cluster on HIF-1alpha expression contributes to clinically relevant radioresistant cells: an in vitro study.
    Cytotechnology. 72:141-153.2020.
  • Li X, Hattori A, Takahashi S, Goto Y, Harada H, Kakeya H.
    UCHL1 promotes HIF-1-dependent tumor cell malignancy in spheroid models.
    Cancer Sci. 111:239-252. 2020.
  • Koyasu S, Shimizu Y, Morinibu A, Saga T, Nakamoto Y, Togashi K, *Harada H.
    Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-accetate PET imaging.
    Journal of Neurooncol. 145:441-447. 2019.
  • Nagao A, Kobayashi M, Koyasu S, Chow CCT, *Harada H.
    HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance.
    Int J Mol Sci. 20:238. 2019.
  • Oe M, Miki K, Mu H, Harada H, Morinibu A, Ohe K.
    pH-responsive cy5 dyes having nucleophilic substituents for molecular imaging.
    Tetrahedron Letters. 59:3317-3321. 2018.
  • Katagiri T, Kobayashi M, Yoshimura M, Morinibu A, Itasaka S, Hiraoka M, *Harada H.
    HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by upregulating expression and secretion of Sonic hedgehog.
    Oncotarget. 9:10525-10535. 2018.
  • Koyasu S, Kobayashi M, Goto Y, Hiraoka M, *Harada H.
    Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge.
    Cancer Sci. 109:560-571. 2018.
  • Sumi C, Okamoto A, Tanaka H, Kusunoki M, Shoji T, Uba T, Adachi T, Iwai T, Nishi K, Harada H, Bono H, Matsuo Y, Hirota K.
    Suppression of mitochondrial oxygen metabolism mediated by the transcription factor HIF-1 alleviates propofol-induced cell toxicity.
    Sci Rep. 9:8987. 2018.
  • Kobayashi M, Morinibu A, Koyasu S, Goto Y, Hiraoka M, *Harada H.
    A circadian clock gene, PER2, activates HIF-1 as an effector molecule for recruitment of HIF-1alpha to promoter regions of its downstream genes.
    FEBS J. 284:3804-3816. 2017.
  • Goto Y, Koyasu S, Kobayashi M, *Harada H.
    The emergingroles of the ubiquitination/deubiquitination system in tumor radioresistance regarding DNA damage response, cell cycle regulation, hypoxic responses, and antioxidant properties: Insight into the development of novel radiosensitizing strategies.
    Mutation Res. 803-805:76-81. 2017.
  • Nakashima R, Goto Y, Koyasu S, Kobayashi M, Morinibu A, Yoshimura M, Hiraoka M, Hammond EM, Harada H,.
    UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization.
    Scientific Reports. 7:6879. 2017.
  • Miki K, Kojima K, Oride K, Harada H, Morinibu A, Ohe K.
    pH-responsive near-infrared fluorescent cyanine dyes for molecular imaging based on pH sensing.
    Chemical Communications. 53:7792-7795. 2017.
  • Okamoto A, Sumi C, Tanaka H, Kusunoki M, Iwai T, Nishi K, Matsuo Y, Harada H, Takenaga K, Bono H, Hirota K..
    HIF-1-mediated suppression of mitochondria electron transport chain function confers resistance to lidocaine-induced cell death.
    Scientific Reports. 7:3816. 2017.
  • Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H, Hijiya K, Aoyama A, Sato T, Sonobe M, Harada H, Date H.
    Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX espression.
    Cancer Medicine. 6:288-297. 2017.
  • Daijo H, Hoshino Y, Kai S, Suzuki K, Nishi K, Matsuo Y, Harada H, Hirota K.
    Cigarette smoke reversibly activates hypoxia-inducible factor 1 in a reactive oxygen species-dependent manner.
    Scientific Reports. 6:34424. 2016..
  • Yeom CJ, Zeng L, Goto Y, Morinibu A, Zhu Y, Shinomiya K, Kobayashi M, Itasaka S, Yoshimura M, HurCG, Kakeya H, Hammond EM, Hiraoka M, *Harada H.
    LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis.
    Oncotarget. 11670. 2016.
  • Yamaguchi R, Harada H, Hirota K.
    VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway.
    Tumor Biology. 37:13295-13306. 2016
  • *Harada H.
    Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radiaresistance.
    J Radiat Res. 57:99-105. 2016.
  • Gaowa A, Horibe T, Kohno M, Harada H, Hiraoka M, Kawakami K.
    Potent anti-tutor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases.
    Clin Exp Metastasis. 33:87-95. 2016.
  • Koyasu S, Tsuji Y, Harada H, Nakamoto Y, Nobashi T, Kimura H, Sano K, Koizumi K, Hamaji M, Togashi K.
    Evaluation of tumor-associated stroma and its relationship with tumor hypoxia using dynamic contrast-enhanced CT and 18F-misonidazole PET in murine tumor models.
    Radiology. 278:734-741. 2016.
  • Olcina MM, Leszczynska K, Senra JM, Isa N, Harada H, Hammond EM.
    H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK.
    Oncogene. 35:793-799. 2016.
  • Inoue M, Yoshimura M, Kobayashi M, Morinibu A, Itasaka S, Hiraoka M, *Harada H.
    PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Scientific Reports. 5:15666. 2015.
  • Tanaka S, Harada H, Hiraoka M.
    A novel method to visually determine the intracellular pH of xenografted tumor in vivo by utilizing fluorescent protein as an indicator.
    Biochem Biophys Res Commun. 464:1151-1156. 2015.
  • Zeng L, Morinibu A, Kobayashi M, Zhu Y, Wang X, Goto Y, Yeom CJ, Zhao T, Hirota K, Shinomiya K, Itasaka S, Yoshimura M, Guo G, Hammond EM, Hiraoka M, *Harada H.
    Aberrant IDH3alpha expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.
    Oncogene. 34:4758-4766. 2015.
  • Matsuyama T, Tanaka T, Tatsumi K, Daijo H, Kai S, Harada H, Fukuda K.
    Midazolam inhibits the hypoxia-induced up-regulation of erythropoietin in the central nervous system
    Euro J Pharmacol. 761:189-198. 2015.
  • Gaowa A, Horibe T, Kohno M, Tabata Y, Harada H, Hiraoka M, Kawakami K.
    Enhancement of anti-tumor activity of hybrid peptide by conjugation with carboxymethyl dextran via disulfide linkers.
    Eur J Pharm Biopharm. 92:228-236. 2015.
  • Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, *Harada H.
    UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on ​HIF-1α.
    Nature Communications. 6: 6153.2015.
  • Miki K, Kimura A, Inoue T, Matsuoka H, Harada H, Hiraoka M, Ohe K.
    Synthesis of Biocompatible Polysaccharide Analogues and Their Application to In Vivo
    Optical Tumor Imaging.
    Bull Chem Soc Jpn. 88:792-803. 2015.
  • Wu JB, Shao C, Li X, Shi C, Li Q, Hu P, Chen YT, Dou X, Sahu D, Li W, Harada H, Zhang Y, Wang R, Zhau HE, Chung LW.
    Near-infraredfluorescence imaging of cancer mediated by tumor hypoxia and HIF1α/OATPs signaling axis.
    Biomaterials. 35: 8175-8185. 2014.
  • Miki K, Hashimoto H, Inoue T, Matsuoka H, Harada H, Hiraoka M, Ohe K.
    Sonication-Induced Formation of Size-Controlled Self-Assemblies of Amphiphilic Janus-Type Polymers as Optical Tumor Imaging Agents.
    Small. 10: 3119-3130. 2014.
  • Ohnishi K, Tani T, Bando S, Kubota N, Fujii Y, Hatano O, Harada H.
    Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroid.
    Int J Oncol. 45: 581-586. 2014.
  • Zhao T, Zhu Y, Morinibu A, Kobayashi M, Shinomiya K, Itasaka S, Yoshimura M, Guo G, Hiraoka M, *Harada H.
    HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs.
    Sci Rep. 4:3793. 2014.
  • Gaowa A, Horibe T, Kohno M, Sato K, Harada H, Hiraoka M, Tabata Y, Kawakami K.
    Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo.
    J Control Release. 176:1-7. 2014.
  • Fujita M, Sasanuma H, Yamamoto NK, Harada H, Kurosawa A, Adachi N, Omura M, Hiraoka M, Takeda S, Hirota K.
    Interference in DNA replication can cause mitotic chromosomal breakage unassociated with double-strand breaks.
    PLoS One. 8:e60043. 2013.
  • Zhu Y, Zhao T, Itasaka S, Zeng L, Yeom CJ, Hirota K, Suzuki K, Morinibu A, Shinomiya K, Ou G, Yoshimura M, Hiraoka M, *Harada H.
    Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells.
    Oncogene. 32:2058-2068. 2013.
  • Yoshimura M, Itasaka S, Harada H, Hiraoka M.
    Microenvironment and radiation therapy.
    Biomed Res Intl. 2013:685308-685320. 2013
  • Yeom CJ, Goto Y, Zhu Y, Hiraoka M, *Harada H.
    Microenvironments and Cellular Characteristics in the Micro Tumor Cords of Malignant Solid Tumors.
    Int J Mol Sci. 13:13949-13965. 2012.
  • Miki K, Nakano K, Matsuoka H, Yeom CJ, Harada H, Hiraoka M, Ohe K.
    Amphiphilic Brush-Like Copolymers Involving Hydrophobic Amino Acid- and Oligopeptide-Side Chains for Optical Tumor Imaging In Vivo.
    Bull Chem Soc Jpn. 85:1277-1286. 2012.
  • *Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ, Hiraoka M.
    Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.
    Nature Communications. 3: 783. 2012.
  • Yoshimura M, Hiraoka M, *Harada H.
    Molecularly based Chemoradiotherapy and High-Precision Radiotherapy. Tan D, Lynch H (eds).
    Principles of Molecular Diagnostics and Personalized Cancer Medicine. Chapter 68: pp909-921. Lippincott Williams & Milkins. 2012.
  • Kai S, Tanaka T, Daijo T, Harada H, Kishimoto S, Suzuki K, Takabuchi S, Takenaga K, Fukuda K, Hirota K.
    Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von Hippel-Lindau- and mitochondoria-dependent manner.
    Antioxid Redox Signal. 16: 203-216. 2012.
  • Saha D, Dunn H, Zhou H, Harada H, Hiraoka M, Mason RP, Zhao D.
    In vivo bioluminescence imaging of tumor hypoxia dynamics of breast cancer brain metastasis in a mouse model.
    J Vis Exp. 56 pii:3175. doi: 1.3791/3175. 2011.
  • Miki K, Oride K, Kimura A, Kuramochi Y, Matsuoka H, Harada H, Hiraoka M, Ohe K.
    Influence of side chain length on fluorescence intensity of ROMP-based polymeric nanoparticles and their tumor specificity in in vivo tumor imaging.
    Small. 7: 3536-3547. 2011.
  • Yeom CJ, Zeng L, Zhu Y, Hiraoka M, *Harada H.
    Strategies to assess hypoxic/HIF-1-active cancer cells for the development of innovative radiation therapy.
    Cancers. 3: 3610-3631. 2011.
  • *Harada H.
    How can we overcome tumor hypoxia in radiation therapy?
    J Radiat Res. 52: 545-556. 2011.
  • Daijo H, Kai S, Tanaka T, Wakamatsu T, Kishimoto S, Suzuki K, Harada H, Takabuchi S, Adachi T, Fukuda R, Hirota K.
    Fentanyl activates hypoxia-inducible factor 1 in neural SH-SY5Y cells and mice under non-hypoxic conditions in a m-opioid receptor-dependent manner.
    Eur J Pharm. 667: 144-152. 2011.
  • Miki K, Kimura A, Oride K, Kuramochi Y, Matsuoka H, Harada H, Hiraoka M, Ohe K.
    High-contrast fluorescence tumor imaging in vivo utilizing nanoparticles of amphiphilic dual brush-like copolymers produced by ROMP and click reaction.
    Angew Chem. Int. Ed. Engl. 50: 6567-6570. 2011.
  • Maki T, Ihara M, Fujita Y, Nambu T, Harada H, Ito H, Nakao K, Tomimoto H, Takahashi R.
    Aigiogenic roles of adrenomodulin through VEGF induction.
    NeuroReport. 22: 442-427. 2011.
  • *Harada H.
    Gene Therapy Strategy for Tumor Hypoxia.
    Targets in Gene Therapy. 11: 185-200. 2011.
  • Makino A, Harada H, Okada T, Kimura H, Amano H, Saji H, Hiraoka M, Kimura S.
    Effective encapsulation of a new cationic gadolinium chelate into apoferitin and its evaluation as a MRI contrast agent.
    Nanomedicine. 7: 638-646. 2011.
  • Maki T, Ihara M, Fujita Y, Nambu T, Miyashita K, Yamada M, Washida K, Nishio K, Ito H, Harada H, Yokoi H, Arai H, Itoh H, Nakao K, Takahashi R, Tomimoto H.
    Angiogenic and vasoprotective effects of adrenomedulin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice.
    Stroke. 42: 1122-1128. 2011.
  • Cilek MZ, Hirohata S, Hatipoglu OF, Ogawa H, Miyoshi T, Inagaki J, Ohtsuki T, Harada H, Kamikawa S, Kusachi S, Ninomiya Y.
    AHR, a novel acute hypoxia-response sequence, drives reporter gene under hypoxia in vitro and in vivo.
    Cell Biol Int. 35: 1-8. 2011.
  • Kumar D, Kumar NM, Akamatsu K, Kusaka E, Harada H and Ito T.
    Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
    Bioorg Med Chem Lett. 20: 3916-3919. 2010.
  • Komatsu H, Harada H, Tanabe K, Hiraoka M, Nishimoto S.
    Indolequinone-rhodol conjugate as fluorescent probe for hypoxic cells: enzymatic activation and fluorescence properties.
    MedChemComm. 1: 50-53. 2010.
  • *Harada H, Hiraoka M.
    Hypoxia-inducible factor 1 in Tumor Radioresistance.
    Current Signal Transduction Therapy. 5:188-196. 2010.
  • Zhao T, *Harada H, Teramura Y, Tanaka S, Itasaka S, Moriniibu A, Shinomiya K, Zhu Y, Hanaoka H, Iwata H, Saji H, Hiraoka M.
    A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells.
    J Control Release. 144: 109-114. 2010.
  • Miki K, Oride K, Inoue S, Kuramochi Y, Nayak RR, Matsuoka H, Harada H, Hiraoka M, Ohe K.
    Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticle for enhanced tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PEGylation.
    Biomaterials. 31:934-942. 2010.
  • Tanabe K, Komatsu H, Harada H, Hiraoka M, Nishimoto S.
    Monitoring of Hypoxia-selective Enzymatic Reduction of Indolequinone derivative by 19F-NMR.
    Photomedicine and Photobiology. 31:31-32. 2009.
  • *Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M.
    The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors.
    J Biol Chem. 284: 5332-5342. 2009.
  • Wakamatsu T, Tanaka T, Oda S, Nishi K, Harada H, Daijo H, Takabuchi S, Fukuda K, Hirota K.
    The intravenous anesthetics barbiturates inhibit hypoxia-inducible factor 1 activation.
    Euro J Pharm. 617:17-22. 2009.
  • *Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, Shinomiya K, Hiraoka M.
    Treatment regimen determines whether a HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
    Br J Cancer. 100:747-757. 2009.
  • Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M.
    The HIF-1-active microenvironment: An environmental target for cancer therapy.
    Adv Drug Deliv Rev. 61:623-32. 2009.
  • Ou G, Itasaka S, Zeng L, Shibuya K, Yi J, Harada H, Hiraoka M.
    HIF imaging is useful to determine the timing of combining Bevacizumab with radiation.
    Int J Radiat Oncol Biol Phys. 75:463-467. 2009.
  • Tanabe K, Harada H, Narazaki M, Tanaka K, Inafuku K, Komatsu H, Ito T, Yamada H, Chujo Y, Matsuda T, Hiraoka M, Nishimoto S.
    Monitoring of biological one-electron reduction by 19F-NMR using hypoxia selective activation of a 19F-labeled indolequinone derivative.
    J Am Chem Soc. 131:15982-15983. 2009.
  • *Harada H, and Hiraoka M.
    Protein Transduction Domain-mediated Delivery of Anti-cancer Drugs and Proteins. Lu Y and Mahato RI (eds).
    Pharmaceutical Perspectives of Cancer Therapeutics. pp297-319. Springer. 2009.
  • Miki K, Kuramochi Y, Oride K, Inoue S, Harada H, Hiraoka M, Ohe K.
    Ring-Opening Metathesis Polymerization-Based Synthesis of ICG-Containing Amphiphilic Triblock Copolymers for in Vivo Tumor Imaging.
    Bioconjugate Chem. 20:511-517. 2009.
  • Hirata N, Fujisawa Y, Tanabe K, Harada H, Hiraoka M, Nishimoto S.
    Radiolytic activation of cytarabine prodrug possessing 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
    Org Biomol Chem. 7:651-654. 2009.
  • Zeng L, Ou G, Itasaka S, *Harada H, Xie X, Shibuya K, Kondoh S, Morinibu A, Shinomiya K, Hiraoka M.
    TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis.
    Cancer Sci.99:2327-2335. 2008.
  • *Harada H, Xie X, Itasaka S, Zeng L, Zhu X, Morinibu A, Shinomiya K, Hiraoka M, (HH and XX contributed equally to this work.).
    Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors.
    Biochem Biophys Res Commun. 373:533-538. 2008.
  • Tanabe K, Hirata N, Harada H, Hiraoka M, and Nishimoto S.
    Fluorescence Imaging of Hypoxia: One-Electron Reduction and Fluorescence Emission Characteristics of Indolequinone-Coumarin Conjugate.
    ChemBioChem. 9: 426-432. 2008.
  • Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M and Hiraoka M.
    Significance of HIF-1-active cells in angiogenesis and radioresistance.
    Oncogene. 26:7508-7516. 2007.
  • Liu J, *Harada H, Ogura M, Shibata T and Hiraoka M.
    Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumor xenografts.
    Br J Cancer. 96: 1871-1878. 2007.
  • *Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, Shinomiya K, Hiraoka M.
    The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts.
    Biochem Biophys Res Commun. 360: 791-796. 2007.
  • Tanaka S, Kizaka-Kondoh S, Harada H and Hiraoka M.
    Development of a novel fluorescent imaging probe for tumor hypoxia by use of a fusion protein with oxygen-dependent degradation domain of HIF-1alpha.
    Progress in Biomedical Optics and Imaging. 8: 644901-644908. 2007.
  • Tanabe K, Hirata N, Harada H, Hiraoka M, and Nishimoto S.
    One-Electron Reduction Characteristics of Indolequinone-Coumarin Conjugate as Hypoxia Imaging Probe.
    Photomedicine and Photobiology. 29:23-26. 2007.
  • *Harada H, Kizaka-Kondoh S, Hiraoka M.
    Antitumor Protein Therapy; Application of the Protein Transduction Domain to Development of a Protein Drug for Cancer Treatment.
    Breast Cancer. 13: 16-26. 2006.
  • Harada H, Kizaka-Kondoh S, Hiraoka M.
    Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.
    FEBS Letters. 580: 5718-5722. 2006.
  • Harada H. Shibuya K. and Hiraoka M.
    Combination of Antimetabolites and Ionizing Radiation. Medical Radiology: Radiation Oncology: Brady LW. Heilmann H-P. and Molls M. (ed).
    Multimodal Concepts for Integration of Cytotoxic Drugs. pp19-34. Springer. 2006.
  • Zhang Z, Harada H, Tanabe K, Hatta H, Hiraoka M, Nishimoto SI.
    Aminopeptidase N/CD13 targeting fluorescent probes: Synthesis and application to tumor cell imaging.
    Peptides. 26: 2182-2187. 2005.
  • Ogura M, Shibata T, Yi J, Liu J, Qu R, Harada H, Hiraoka M.
    A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas.
    Cancer Sci. 96: 288-94. 2005.
  • Harada H, Kizaka-Kondoh S, Hiraoka M.
    Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animal.
    Mol Imaging. 4: 182-193. 2005.
  • Liu J, Qu R, Ogura M, Shibata T, *Harada H, Hiraoka M.
    Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts.
    J Radiat Res. 46: 93-102. 2005.
  • Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M.
    Tumor hypoxia: A target for selective cancer therapy.
    Cancer Sci. 94: 1021-1028. 2003.
  • Harada H, Hiraoka M, Kizaka-Kondoh S.
    Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
    Cancer Res. 62: 2013-2018. 2002.

LINKS

 





aaa








  ※その他のリンクはこちら


LAB INFORMATION

京都大学大学院
生命科学研究科
がん細胞生物学分野

〒606-8501
京都市左京区吉田近衛町
TEL: 075-753-7560
FAX: 075-753-7564